NVIDIA’s AI Ambitions Fuel Analyst Optimism and Pharma Partnership
Wall Street's bullish stance on Nvidia intensifies as Jefferies raises its price target to $275, citing undervaluation relative to long-term growth projections. The stock trades at mid-teens multiples to 2027 estimates, with analysts anticipating consecutive earnings beats.
A landmark $1 billion AI co-innovation lab with Eli Lilly positions NVIDIA at the intersection of tech and biopharma. The five-year initiative leverages NVIDIA's computational prowess to model complex biological systems, potentially accelerating drug discovery timelines.
J.P. Morgan joins Jefferies in maintaining Buy ratings, reflecting institutional confidence in NVIDIA's dual dominance of AI hardware and vertical applications. The partnership exemplifies how GPU technology is becoming foundational across industries beyond traditional computing.
